MEDI-3617 / AstraZeneca - LARVOL DELTA

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: F. Stephen Hodi, MD | Active, not recruiting ➔ Completed

Metastases • Trial completion • Melanoma • Oncology • Solid Tumor

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: F. Stephen Hodi, MD | Trial completion date: Mar 2023 ➔ Mar 2024

Metastases • Trial completion date • Melanoma • Oncology • Solid Tumor

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: F. Stephen Hodi, MD | Trial primary completion date: Dec 2022 ➔ Mar 2023

Metastases • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: F. Stephen Hodi, MD | Trial completion date: Sep 2022 ➔ Mar 2023 | Trial primary completion date: Jul 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: F. Stephen Hodi, MD | Trial completion date: Mar 2022 ➔ Sep 2022 | Trial primary completion date: Jul 2021 ➔ Jul 2022

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. (PubMed, J Immunother Cancer) - P1 | "Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma. Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration."

Clinical • Journal • P1 data • Dermatology • Fatigue • Immune Modulation • Inflammation • Melanoma • Oncology • Pruritus • Solid Tumor • CD4 • CD8 • CTLA4 • ICOS • IL10 • IL2

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: F. Stephen Hodi, MD; Trial completion date: Dec 2021 ➔ Mar 2022

Clinical • Trial completion date • Melanoma • Oncology • Solid Tumor

Angiopoietin inhibitors: A review on targeting tumor angiogenesis. (PubMed, Eur J Pharmacol) - "Drugs studied in the article are selective as well as non-selective inhibitors of angiopoietin 2 like Trebananib (AMG 386), AMG 780, REGN 910, CVX 060, MEDI 3617 and dual inhibitors of angiopoietin 2 and VEGF like Vanucizumab and RG7716. The angiopoietin inhibitors show promising results alone and in combination with VEGF inhibitors in various malignancies."

Journal • Review • Immunology • Inflammation • Oncology

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: F. Stephen Hodi, MD; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: F. Stephen Hodi, MD; Trial completion date: Dec 2020 ➔ Jun 2021; Trial primary completion date: Jun 2020 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. (PubMed, Curr Oncol Rep) - "Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility."

Clinical • Journal • Review • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

AstraZeneca: Q4 & FY 2014 Results (AstraZeneca) - Anticipated completion of P1 trial for solid tumours and ovarian cancer in Q3 2016

Anticipated trial completion date • Oncology • Ovarian Cancer

AstraZeneca: Q3 FY 2016 Results (AstraZeneca) - Discontinuation in solid tumors due to safety/efficacy reason

Discontinued • Oncology

AstraZeneca: Q1 2015 Results (AstraZeneca) - Anticipated enrollment completion of P1 trial (NCT01248949) for solid tumors and ovarian cancer in Q2 2015; Anticipated topline data from P1 trial (NCT01248949) for solid tumors and ovarian cancer in Q3 2017

Anticipated enrollment status • Anticipated P1 data • Oncology • Ovarian Cancer

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined With Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. (PubMed, Clin Cancer Res) - " Recommended MEDI3617 monotherapy dosage is 1500 mg Q3W or 1000 mg Q2W, except in ovarian cancer. Although peripheral edema has occurred with other Ang2 inhibitors, the severity and duration seen here in ovarian cancer potentially identifies a new, clinically significant safety signal for this class of agents. Based on limited clinical activity, MEDI3617 development was discontinued."

Journal • P1 data